Naltrexone / LDN
FDA-approved · Grade C
Goals
healing, cognition, sleep, gut, immune
Evidence
4 RCT / 3 animal / 2 in vitro
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
Selank
Research chemical · Grade C
Goals
cognition, sleep, immune
Evidence
3 RCT / 1 animal / 0 in vitro
Typical dose
Intranasal: 250-500 mcg per session (2-5 drops or sprays), 1-2x daily. SubQ: 150-250 mcg daily. Cycles of 10-14 days with breaks standard in Russian protocol; community often runs longer.
Half-life
~2-5 minutes in plasma. Effects last hours per dose via downstream signaling. Rapid peptidase degradation makes oral bioavailability negligible.
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
DSIP
Research chemical · Grade C
Evidence
1 RCT / 6 animal / 1 in vitro
Routes
injectable-sc, nasal
Half-life
In animal studies: the half-life appears even shorter — approximately 4-5 minutes in vivo
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.